primaquine and Inborn Errors of Metabolism

primaquine has been researched along with Inborn Errors of Metabolism in 17 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Research

Studies (17)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Time to Parasitemia for Immunogenicity Population

"Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.~Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy." (NCT01157897)
Timeframe: 280 day (during the study through 6 months aftr challenge)

Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. (NCT01157897)
Timeframe: 7 days after immunization

Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase (NCT01157897)
Timeframe: 28 days following immunization

Reviews

6 reviews available for primaquine and Inborn Errors of Metabolism

Trials

1 trial available for primaquine and Inborn Errors of Metabolism

Other Studies

10 other studies available for primaquine and Inborn Errors of Metabolism